Resistentia Pharmaceuticals AB
🇸🇪Sweden
Safety Study of Anti-IgE Immunotherapy in Allergic Patients
Phase 2
Completed
- Conditions
- Allergy
- Interventions
- Biological: RP 01
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2008-08-18
- Lead Sponsor
- Resistentia Pharmaceuticals AB
- Target Recruit Count
- 42
- Registration Number
- NCT00439621
- Locations
- 🇳🇿
P3 Research, Wellington, New Zealand
© Copyright 2025. All Rights Reserved by MedPath